# PeptideScanner evidence objects: Dalbavancin

Every published version of the records placed with Dalbavancin, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json. Selected public evidence only; not medical advice.

- Objects: 46
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct00678106-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT00678106

> PeptideScanner retained ClinicalTrials.gov record NCT00678106 at 2026-11-16T17:37:42.807Z. Its registry update date was 2009-10-12, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct00678106-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2009-10-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00678106-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct00678106-dalbavancin-v1
- Content SHA-256: `a53a187a9b1ae6a0ed8a72bf13de7e836fb68b30a3225daf16b479881b63308f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT00678106 ([`ctg-observation-nct00678106-2009-10-12-03e01e031b9a`](#source-ctg-observation-nct00678106-2009-10-12-03e01e031b9a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00678106 at 2026-11-16T17:37:42.807Z. Its registry update date was 2009-10-12, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct00678106-2009-10-12-03e01e031b9a`](#source-ctg-observation-nct00678106-2009-10-12-03e01e031b9a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00678106 at 2026-11-16T17:37:42.807Z. Its registry update date was 2009-10-12, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct00678106-2009-10-12-03e01e031b9a`](#source-ctg-observation-nct00678106-2009-10-12-03e01e031b9a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00678106-2009-10-12-03e01e031b9a`](#source-ctg-observation-nct00678106-2009-10-12-03e01e031b9a))

### Sources

<a id="source-ctg-observation-nct00678106-2009-10-12-03e01e031b9a"></a>
- **ClinicalTrials.gov record NCT00678106 · retained source version 2009-10-12:03e01e031b9a212b79c1f97e32ad1a9284d55acf7b11d6a45be5716b7785e4c3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00678106) (`ctg-observation-nct00678106-2009-10-12-03e01e031b9a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00678106." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct00678106-dalbavancin-v1 SHA-256: a53a187a9b1ae6a0ed8a72bf13de7e836fb68b30a3225daf16b479881b63308f.

---

<a id="clinicaltrials-gov-nct01339091-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT01339091

> PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct01339091-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2014-01-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01339091-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct01339091-dalbavancin-v1
- Content SHA-256: `1363c29f7afddb6e23802e47103856c9d2ea3ebe8d5a1c473c536e6068d15b35`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01339091 ([`ctg-observation-nct01339091-2014-01-31-5435808cf1d8`](#source-ctg-observation-nct01339091-2014-01-31-5435808cf1d8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct01339091-2014-01-31-5435808cf1d8`](#source-ctg-observation-nct01339091-2014-01-31-5435808cf1d8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01339091 at 2026-11-16T17:37:42.807Z. Its registry update date was 2014-01-31, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct01339091-2014-01-31-5435808cf1d8`](#source-ctg-observation-nct01339091-2014-01-31-5435808cf1d8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01339091-2014-01-31-5435808cf1d8`](#source-ctg-observation-nct01339091-2014-01-31-5435808cf1d8))

### Sources

<a id="source-ctg-observation-nct01339091-2014-01-31-5435808cf1d8"></a>
- **ClinicalTrials.gov record NCT01339091 · retained source version 2014-01-31:5435808cf1d88dd50b35f1a07c13222e176e19874e99bb3a598050630c3884f1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01339091) (`ctg-observation-nct01339091-2014-01-31-5435808cf1d8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01339091." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct01339091-dalbavancin-v1 SHA-256: 1363c29f7afddb6e23802e47103856c9d2ea3ebe8d5a1c473c536e6068d15b35.

---

<a id="clinicaltrials-gov-nct01946568-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT01946568

> PeptideScanner retained ClinicalTrials.gov record NCT01946568 at 2026-11-16T17:37:42.807Z. Its registry update date was 2015-06-23, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct01946568-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2015-06-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01946568-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct01946568-dalbavancin-v1
- Content SHA-256: `28fde7b91bc2743d81aba99053636c301c063fae68fa8ab26b99c5dc276f5c9e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01946568 ([`ctg-observation-nct01946568-2015-06-23-22ce71dc62a8`](#source-ctg-observation-nct01946568-2015-06-23-22ce71dc62a8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01946568 at 2026-11-16T17:37:42.807Z. Its registry update date was 2015-06-23, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct01946568-2015-06-23-22ce71dc62a8`](#source-ctg-observation-nct01946568-2015-06-23-22ce71dc62a8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01946568 at 2026-11-16T17:37:42.807Z. Its registry update date was 2015-06-23, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct01946568-2015-06-23-22ce71dc62a8`](#source-ctg-observation-nct01946568-2015-06-23-22ce71dc62a8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01946568-2015-06-23-22ce71dc62a8`](#source-ctg-observation-nct01946568-2015-06-23-22ce71dc62a8))

### Sources

<a id="source-ctg-observation-nct01946568-2015-06-23-22ce71dc62a8"></a>
- **ClinicalTrials.gov record NCT01946568 · retained source version 2015-06-23:22ce71dc62a8557044cb16e85cd19feff10db82f4478ddb86bf046b78e7d89c7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01946568) (`ctg-observation-nct01946568-2015-06-23-22ce71dc62a8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01946568." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct01946568-dalbavancin-v1 SHA-256: 28fde7b91bc2743d81aba99053636c301c063fae68fa8ab26b99c5dc276f5c9e.

---

<a id="clinicaltrials-gov-nct02127970-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT02127970

> PeptideScanner retained ClinicalTrials.gov record NCT02127970 at 2026-11-16T17:37:42.807Z. Its registry update date was 2018-09-28, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct02127970-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2018-09-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02127970-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02127970-dalbavancin-v1
- Content SHA-256: `dc2cf7d8a4cfd0e0698a7c0888b9b836a2a800dc826aaa9ace8343fdcdbb53c7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02127970 ([`ctg-observation-nct02127970-2018-09-28-d2c621afc2ae`](#source-ctg-observation-nct02127970-2018-09-28-d2c621afc2ae))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02127970 at 2026-11-16T17:37:42.807Z. Its registry update date was 2018-09-28, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02127970-2018-09-28-d2c621afc2ae`](#source-ctg-observation-nct02127970-2018-09-28-d2c621afc2ae))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02127970 at 2026-11-16T17:37:42.807Z. Its registry update date was 2018-09-28, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02127970-2018-09-28-d2c621afc2ae`](#source-ctg-observation-nct02127970-2018-09-28-d2c621afc2ae))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02127970-2018-09-28-d2c621afc2ae`](#source-ctg-observation-nct02127970-2018-09-28-d2c621afc2ae))

### Sources

<a id="source-ctg-observation-nct02127970-2018-09-28-d2c621afc2ae"></a>
- **ClinicalTrials.gov record NCT02127970 · retained source version 2018-09-28:d2c621afc2ae477141688fb06dba2fa1e36d4b165a70ae21fdd0d0e7366ec9c7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02127970) (`ctg-observation-nct02127970-2018-09-28-d2c621afc2ae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02127970." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02127970-dalbavancin-v1 SHA-256: dc2cf7d8a4cfd0e0698a7c0888b9b836a2a800dc826aaa9ace8343fdcdbb53c7.

---

<a id="clinicaltrials-gov-nct02685033-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT02685033

> PeptideScanner retained ClinicalTrials.gov record NCT02685033 at 2026-11-16T17:37:42.807Z. Its registry update date was 2019-01-04, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct02685033-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2019-01-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02685033-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02685033-dalbavancin-v1
- Content SHA-256: `ecd89d0198bc9ad1223a46ddc8ae441c059c45ddcf076d5b0f9a6d69a37d0eb4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02685033 ([`ctg-observation-nct02685033-2019-01-04-d5c047fdebe1`](#source-ctg-observation-nct02685033-2019-01-04-d5c047fdebe1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02685033 at 2026-11-16T17:37:42.807Z. Its registry update date was 2019-01-04, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02685033-2019-01-04-d5c047fdebe1`](#source-ctg-observation-nct02685033-2019-01-04-d5c047fdebe1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02685033 at 2026-11-16T17:37:42.807Z. Its registry update date was 2019-01-04, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02685033-2019-01-04-d5c047fdebe1`](#source-ctg-observation-nct02685033-2019-01-04-d5c047fdebe1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02685033-2019-01-04-d5c047fdebe1`](#source-ctg-observation-nct02685033-2019-01-04-d5c047fdebe1))

### Sources

<a id="source-ctg-observation-nct02685033-2019-01-04-d5c047fdebe1"></a>
- **ClinicalTrials.gov record NCT02685033 · retained source version 2019-01-04:d5c047fdebe11d5737ec7599c1bfb38085f3f899674661d039a0636fd3b8fd39** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02685033) (`ctg-observation-nct02685033-2019-01-04-d5c047fdebe1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02685033." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02685033-dalbavancin-v1 SHA-256: ecd89d0198bc9ad1223a46ddc8ae441c059c45ddcf076d5b0f9a6d69a37d0eb4.

---

<a id="clinicaltrials-gov-nct02814916-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT02814916

> PeptideScanner retained ClinicalTrials.gov record NCT02814916 at 2026-11-16T17:37:42.807Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct02814916-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-09-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02814916-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02814916-dalbavancin-v1
- Content SHA-256: `4536a694e439f371808fe6359dffb75f6e807ff185477ba5a3952073ca810c80`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02814916 ([`ctg-observation-nct02814916-2024-09-19-d3526df278e8`](#source-ctg-observation-nct02814916-2024-09-19-d3526df278e8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02814916 at 2026-11-16T17:37:42.807Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02814916-2024-09-19-d3526df278e8`](#source-ctg-observation-nct02814916-2024-09-19-d3526df278e8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02814916 at 2026-11-16T17:37:42.807Z. Its registry update date was 2024-09-19, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02814916-2024-09-19-d3526df278e8`](#source-ctg-observation-nct02814916-2024-09-19-d3526df278e8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02814916-2024-09-19-d3526df278e8`](#source-ctg-observation-nct02814916-2024-09-19-d3526df278e8))

### Sources

<a id="source-ctg-observation-nct02814916-2024-09-19-d3526df278e8"></a>
- **ClinicalTrials.gov record NCT02814916 · retained source version 2024-09-19:d3526df278e8962f1388f0fbd5a4203c87bcff17fb7a769b314917877add394b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02814916) (`ctg-observation-nct02814916-2024-09-19-d3526df278e8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02814916." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02814916-dalbavancin-v1 SHA-256: 4536a694e439f371808fe6359dffb75f6e807ff185477ba5a3952073ca810c80.

---

<a id="clinicaltrials-gov-nct02961764-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT02961764

> PeptideScanner retained ClinicalTrials.gov record NCT02961764 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-04-10, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct02961764-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-04-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02961764-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02961764-dalbavancin-v1
- Content SHA-256: `e0e7533c4ed28ead1c81cf497f03c879fa88140fd9d2461fe8e4bf8d0abda9e5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02961764 ([`ctg-observation-nct02961764-2020-04-10-9e6b3865ac22`](#source-ctg-observation-nct02961764-2020-04-10-9e6b3865ac22))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02961764 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-04-10, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02961764-2020-04-10-9e6b3865ac22`](#source-ctg-observation-nct02961764-2020-04-10-9e6b3865ac22))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02961764 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-04-10, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct02961764-2020-04-10-9e6b3865ac22`](#source-ctg-observation-nct02961764-2020-04-10-9e6b3865ac22))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02961764-2020-04-10-9e6b3865ac22`](#source-ctg-observation-nct02961764-2020-04-10-9e6b3865ac22))

### Sources

<a id="source-ctg-observation-nct02961764-2020-04-10-9e6b3865ac22"></a>
- **ClinicalTrials.gov record NCT02961764 · retained source version 2020-04-10:9e6b3865ac22b85a747fe864fbbd74e1565ba513603df657e1f6e771922c93db** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02961764) (`ctg-observation-nct02961764-2020-04-10-9e6b3865ac22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02961764." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct02961764-dalbavancin-v1 SHA-256: e0e7533c4ed28ead1c81cf497f03c879fa88140fd9d2461fe8e4bf8d0abda9e5.

---

<a id="clinicaltrials-gov-nct03233438-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT03233438

> PeptideScanner retained ClinicalTrials.gov record NCT03233438 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-01-18, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct03233438-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2020-01-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03233438-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct03233438-dalbavancin-v1
- Content SHA-256: `85a330b2d704a777ae764eed03f9288792deda4270bec54d1169b1fa9077a772`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03233438 ([`ctg-observation-nct03233438-2020-01-18-43f4dabab11e`](#source-ctg-observation-nct03233438-2020-01-18-43f4dabab11e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03233438 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-01-18, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct03233438-2020-01-18-43f4dabab11e`](#source-ctg-observation-nct03233438-2020-01-18-43f4dabab11e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03233438 at 2026-11-16T17:37:42.807Z. Its registry update date was 2020-01-18, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct03233438-2020-01-18-43f4dabab11e`](#source-ctg-observation-nct03233438-2020-01-18-43f4dabab11e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03233438-2020-01-18-43f4dabab11e`](#source-ctg-observation-nct03233438-2020-01-18-43f4dabab11e))

### Sources

<a id="source-ctg-observation-nct03233438-2020-01-18-43f4dabab11e"></a>
- **ClinicalTrials.gov record NCT03233438 · retained source version 2020-01-18:43f4dabab11eae8f7ff9981f8925c9f3f235fc91ddf62a537e92a53dd1f5c049** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03233438) (`ctg-observation-nct03233438-2020-01-18-43f4dabab11e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03233438." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct03233438-dalbavancin-v1 SHA-256: 85a330b2d704a777ae764eed03f9288792deda4270bec54d1169b1fa9077a772.

---

<a id="clinicaltrials-gov-nct04959799-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT04959799

> PeptideScanner retained ClinicalTrials.gov record NCT04959799 at 2026-11-16T17:37:42.807Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct04959799-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-09-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04959799-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct04959799-dalbavancin-v1
- Content SHA-256: `f88ce68dda89e2d851318d7939865d9c94b04f3a029a917026fff779266bd1e1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04959799 ([`ctg-observation-nct04959799-2022-09-21-868041951483`](#source-ctg-observation-nct04959799-2022-09-21-868041951483))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04959799 at 2026-11-16T17:37:42.807Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct04959799-2022-09-21-868041951483`](#source-ctg-observation-nct04959799-2022-09-21-868041951483))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04959799 at 2026-11-16T17:37:42.807Z. Its registry update date was 2022-09-21, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct04959799-2022-09-21-868041951483`](#source-ctg-observation-nct04959799-2022-09-21-868041951483))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04959799-2022-09-21-868041951483`](#source-ctg-observation-nct04959799-2022-09-21-868041951483))

### Sources

<a id="source-ctg-observation-nct04959799-2022-09-21-868041951483"></a>
- **ClinicalTrials.gov record NCT04959799 · retained source version 2022-09-21:8680419514837375026772d7a40603eb0fabce158fedfa6899427f6f8b0d8470** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04959799) (`ctg-observation-nct04959799-2022-09-21-868041951483`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04959799." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct04959799-dalbavancin-v1 SHA-256: f88ce68dda89e2d851318d7939865d9c94b04f3a029a917026fff779266bd1e1.

---

<a id="clinicaltrials-gov-nct05046860-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT05046860

> PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct05046860-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05046860-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct05046860-dalbavancin-v1
- Content SHA-256: `5b4b52e8e7fdfd79736ef5512e4234785d1fa4710980edad15bfa4a04aa395ce`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05046860 ([`ctg-observation-nct05046860-2026-06-22-768ecbdbdc42`](#source-ctg-observation-nct05046860-2026-06-22-768ecbdbdc42))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct05046860-2026-06-22-768ecbdbdc42`](#source-ctg-observation-nct05046860-2026-06-22-768ecbdbdc42))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05046860 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-06-22, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct05046860-2026-06-22-768ecbdbdc42`](#source-ctg-observation-nct05046860-2026-06-22-768ecbdbdc42))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05046860-2026-06-22-768ecbdbdc42`](#source-ctg-observation-nct05046860-2026-06-22-768ecbdbdc42))

### Sources

<a id="source-ctg-observation-nct05046860-2026-06-22-768ecbdbdc42"></a>
- **ClinicalTrials.gov record NCT05046860 · retained source version 2026-06-22:768ecbdbdc421b88adc36c33ed618369b140e0448f1942e6700f79f9ac1b4a76** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05046860) (`ctg-observation-nct05046860-2026-06-22-768ecbdbdc42`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05046860." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct05046860-dalbavancin-v1 SHA-256: 5b4b52e8e7fdfd79736ef5512e4234785d1fa4710980edad15bfa4a04aa395ce.

---

<a id="clinicaltrials-gov-nct06810583-dalbavancin-v1"></a>

## ClinicalTrials.gov record NCT06810583

> PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin.

- Evidence object: `story:clinicaltrials-gov-nct06810583-dalbavancin:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06810583-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct06810583-dalbavancin-v1
- Content SHA-256: `ce95f97c8b137e71cdfb9c19e28f33750cf375c5182aa32106c344a8637c0acd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06810583 ([`ctg-observation-nct06810583-2026-09-15-d3668a751dea`](#source-ctg-observation-nct06810583-2026-09-15-d3668a751dea))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct06810583-2026-09-15-d3668a751dea`](#source-ctg-observation-nct06810583-2026-09-15-d3668a751dea))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06810583 at 2026-11-16T17:37:42.807Z. Its registry update date was 2026-09-15, and PeptideScanner's reviewed identity mapping was dalbavancin. ([`ctg-observation-nct06810583-2026-09-15-d3668a751dea`](#source-ctg-observation-nct06810583-2026-09-15-d3668a751dea))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06810583-2026-09-15-d3668a751dea`](#source-ctg-observation-nct06810583-2026-09-15-d3668a751dea))

### Sources

<a id="source-ctg-observation-nct06810583-2026-09-15-d3668a751dea"></a>
- **ClinicalTrials.gov record NCT06810583 · retained source version 2026-09-15:d3668a751dea30340acf291aa91655cd639b2283e75dfa6947780c20cfd31beb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06810583) (`ctg-observation-nct06810583-2026-09-15-d3668a751dea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06810583." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#clinicaltrials-gov-nct06810583-dalbavancin-v1 SHA-256: ce95f97c8b137e71cdfb9c19e28f33750cf375c5182aa32106c344a8637c0acd.

---

<a id="fda-drugs-anda217591-v1"></a>

## Drugs@FDA application ANDA217591

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217591:v1`
- Evidence domain: Regulatory
- Date in source: 2025-11-10
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217591/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda217591-v1
- Content SHA-256: `18f9c60d9db9eb09ab7142fa8e378d15e4ffb416f9ff19d203984149667bd89f`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217591 ([`fda-drugs-anda217591-2025-11-10-32ff2e18c189`](#source-fda-drugs-anda217591-2025-11-10-32ff2e18c189))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda217591-2025-11-10-32ff2e18c189`](#source-fda-drugs-anda217591-2025-11-10-32ff2e18c189))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217591 with status AP dated 2025-11-10, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda217591-2025-11-10-32ff2e18c189`](#source-fda-drugs-anda217591-2025-11-10-32ff2e18c189))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217591-2025-11-10-32ff2e18c189`](#source-fda-drugs-anda217591-2025-11-10-32ff2e18c189))

### Sources

<a id="source-fda-drugs-anda217591-2025-11-10-32ff2e18c189"></a>
- **Drugs@FDA application ANDA217591 · original submission status AP · 2025-11-10 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217591%22&limit=1) (`fda-drugs-anda217591-2025-11-10-32ff2e18c189`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217591." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda217591-v1 SHA-256: 18f9c60d9db9eb09ab7142fa8e378d15e4ffb416f9ff19d203984149667bd89f.

---

<a id="fda-drugs-anda218602-v1"></a>

## Drugs@FDA application ANDA218602

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218602:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-26
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218602/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda218602-v1
- Content SHA-256: `1bd3cba73702b59526be7fe1c590863717327fcb8106b61632173ff3198ddd95`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218602 ([`fda-drugs-anda218602-2026-02-26-ca476baa2dbc`](#source-fda-drugs-anda218602-2026-02-26-ca476baa2dbc))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda218602-2026-02-26-ca476baa2dbc`](#source-fda-drugs-anda218602-2026-02-26-ca476baa2dbc))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218602 with status AP dated 2026-02-26, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda218602-2026-02-26-ca476baa2dbc`](#source-fda-drugs-anda218602-2026-02-26-ca476baa2dbc))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218602-2026-02-26-ca476baa2dbc`](#source-fda-drugs-anda218602-2026-02-26-ca476baa2dbc))

### Sources

<a id="source-fda-drugs-anda218602-2026-02-26-ca476baa2dbc"></a>
- **Drugs@FDA application ANDA218602 · original submission status AP · 2026-02-26 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218602%22&limit=1) (`fda-drugs-anda218602-2026-02-26-ca476baa2dbc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218602." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda218602-v1 SHA-256: 1bd3cba73702b59526be7fe1c590863717327fcb8106b61632173ff3198ddd95.

---

<a id="fda-drugs-anda218929-v1"></a>

## Drugs@FDA application ANDA218929

> The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda218929:v1`
- Evidence domain: Regulatory
- Date in source: 2025-11-26
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda218929/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda218929-v1
- Content SHA-256: `b9177b3e076080ec00c5fbc73e0a949ef2837237fcc715c18b1ec29197eb194f`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA218929 ([`fda-drugs-anda218929-2025-11-26-af64b8414c5b`](#source-fda-drugs-anda218929-2025-11-26-af64b8414c5b))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda218929-2025-11-26-af64b8414c5b`](#source-fda-drugs-anda218929-2025-11-26-af64b8414c5b))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 218929 with status AP dated 2025-11-26, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda218929-2025-11-26-af64b8414c5b`](#source-fda-drugs-anda218929-2025-11-26-af64b8414c5b))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda218929-2025-11-26-af64b8414c5b`](#source-fda-drugs-anda218929-2025-11-26-af64b8414c5b))

### Sources

<a id="source-fda-drugs-anda218929-2025-11-26-af64b8414c5b"></a>
- **Drugs@FDA application ANDA218929 · original submission status AP · 2025-11-26 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA218929%22&limit=1) (`fda-drugs-anda218929-2025-11-26-af64b8414c5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA218929." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda218929-v1 SHA-256: b9177b3e076080ec00c5fbc73e0a949ef2837237fcc715c18b1ec29197eb194f.

---

<a id="fda-drugs-anda219465-v1"></a>

## Drugs@FDA application ANDA219465

> The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda219465:v1`
- Evidence domain: Regulatory
- Date in source: 2025-10-23
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda219465/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda219465-v1
- Content SHA-256: `d805d165802e61a661a541a60e2d631ff2be7b6acd71170b6512264d39f33668`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA219465 ([`fda-drugs-anda219465-2025-10-23-a679cba863af`](#source-fda-drugs-anda219465-2025-10-23-a679cba863af))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda219465-2025-10-23-a679cba863af`](#source-fda-drugs-anda219465-2025-10-23-a679cba863af))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 219465 with status AP dated 2025-10-23, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda219465-2025-10-23-a679cba863af`](#source-fda-drugs-anda219465-2025-10-23-a679cba863af))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda219465-2025-10-23-a679cba863af`](#source-fda-drugs-anda219465-2025-10-23-a679cba863af))

### Sources

<a id="source-fda-drugs-anda219465-2025-10-23-a679cba863af"></a>
- **Drugs@FDA application ANDA219465 · original submission status AP · 2025-10-23 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA219465%22&limit=1) (`fda-drugs-anda219465-2025-10-23-a679cba863af`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA219465." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda219465-v1 SHA-256: d805d165802e61a661a541a60e2d631ff2be7b6acd71170b6512264d39f33668.

---

<a id="fda-drugs-anda219604-v1"></a>

## Drugs@FDA application ANDA219604

> The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda219604:v1`
- Evidence domain: Regulatory
- Date in source: 2026-06-04
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda219604/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda219604-v1
- Content SHA-256: `865c82d97dee784c187c5ab10c4cf6ee7967f9c07c6d62b6545b83bf803114d8`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA219604 ([`fda-drugs-anda219604-2026-06-04-7233cd7bdf93`](#source-fda-drugs-anda219604-2026-06-04-7233cd7bdf93))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda219604-2026-06-04-7233cd7bdf93`](#source-fda-drugs-anda219604-2026-06-04-7233cd7bdf93))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 219604 with status AP dated 2026-06-04, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-anda219604-2026-06-04-7233cd7bdf93`](#source-fda-drugs-anda219604-2026-06-04-7233cd7bdf93))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda219604-2026-06-04-7233cd7bdf93`](#source-fda-drugs-anda219604-2026-06-04-7233cd7bdf93))

### Sources

<a id="source-fda-drugs-anda219604-2026-06-04-7233cd7bdf93"></a>
- **Drugs@FDA application ANDA219604 · original submission status AP · 2026-06-04 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA219604%22&limit=1) (`fda-drugs-anda219604-2026-06-04-7233cd7bdf93`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA219604." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-anda219604-v1 SHA-256: 865c82d97dee784c187c5ab10c4cf6ee7967f9c07c6d62b6545b83bf803114d8.

---

<a id="fda-drugs-nda021883-v1"></a>

## Drugs@FDA application NDA021883

> The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda021883:v1`
- Evidence domain: Regulatory
- Date in source: 2014-05-23
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda021883/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-nda021883-v1
- Content SHA-256: `e746354c93b4beebe07a9fc830c9a9f150fe4b16e219a3fe2c0802b2dd164692`

### Claims and source pins

#### Headline

Drugs@FDA application NDA021883 ([`fda-drugs-nda021883-2014-05-23-f6604b28b1a6`](#source-fda-drugs-nda021883-2014-05-23-f6604b28b1a6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-nda021883-2014-05-23-f6604b28b1a6`](#source-fda-drugs-nda021883-2014-05-23-f6604b28b1a6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 021883 with status AP dated 2014-05-23, and names dalbavancin hydrochloride among the application record's active ingredients. ([`fda-drugs-nda021883-2014-05-23-f6604b28b1a6`](#source-fda-drugs-nda021883-2014-05-23-f6604b28b1a6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda021883-2014-05-23-f6604b28b1a6`](#source-fda-drugs-nda021883-2014-05-23-f6604b28b1a6))

### Sources

<a id="source-fda-drugs-nda021883-2014-05-23-f6604b28b1a6"></a>
- **Drugs@FDA application NDA021883 · original submission status AP · 2014-05-23 · dataset 2026-11-16** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021883%22&limit=1) (`fda-drugs-nda021883-2014-05-23-f6604b28b1a6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA021883." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#fda-drugs-nda021883-v1 SHA-256: e746354c93b4beebe07a9fc830c9a9f150fe4b16e219a3fe2c0802b2dd164692.

---

<a id="federal-register-2014-02942-v1"></a>

## Federal Register notice 2014-02942

> The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

- Evidence object: `story:federal-register-2014-02942:v1`
- Evidence domain: Regulatory
- Date in source: 2014-02-12
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2014-02942/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2014-02942-v1
- Content SHA-256: `ca4266ae60ab7c5804d968f1bcba55d0e7c0b991cc5c21294bc6beea13b2c1ea`

### Claims and source pins

#### Headline

Federal Register notice 2014-02942 ([`federal-register-2014-02942-f8431d4b4af5`](#source-federal-register-2014-02942-f8431d4b4af5))

#### Summary

The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2014-02942-f8431d4b4af5`](#source-federal-register-2014-02942-f8431d4b4af5))

#### Paragraph 1

The Federal Register published notice 2014-02942, attributed to FDA and its parent HHS department, on 2014-02-12. Its official title is “Anti-Infective Drugs Advisory Committee; Notice of Meeting,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2014-02942-f8431d4b4af5`](#source-federal-register-2014-02942-f8431d4b4af5))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2014-02942-f8431d4b4af5`](#source-federal-register-2014-02942-f8431d4b4af5))

### Sources

<a id="source-federal-register-2014-02942-f8431d4b4af5"></a>
- **Federal Register notice 2014-02942 · published 2014-02-12 · Anti-Infective Drugs Advisory Committee; Notice of Meeting** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2014-02-12/pdf/2014-02942.pdf) (`federal-register-2014-02942-f8431d4b4af5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2014-02942." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2014-02942-v1 SHA-256: ca4266ae60ab7c5804d968f1bcba55d0e7c0b991cc5c21294bc6beea13b2c1ea.

---

<a id="federal-register-2018-02768-v1"></a>

## Federal Register notice 2018-02768

> The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

- Evidence object: `story:federal-register-2018-02768:v1`
- Evidence domain: Regulatory
- Date in source: 2018-02-12
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2018-02768/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2018-02768-v1
- Content SHA-256: `fd7ae3ca1130b771f35d5ec41adcf5e597ee821a30a0384eca84f28f258f4ba1`

### Claims and source pins

#### Headline

Federal Register notice 2018-02768 ([`federal-register-2018-02768-12e5f5b2b538`](#source-federal-register-2018-02768-12e5f5b2b538))

#### Summary

The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2018-02768-12e5f5b2b538`](#source-federal-register-2018-02768-12e5f5b2b538))

#### Paragraph 1

The Federal Register published notice 2018-02768, attributed to FDA and its parent HHS department, on 2018-02-12. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2018-02768-12e5f5b2b538`](#source-federal-register-2018-02768-12e5f5b2b538))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2018-02768-12e5f5b2b538`](#source-federal-register-2018-02768-12e5f5b2b538))

### Sources

<a id="source-federal-register-2018-02768-12e5f5b2b538"></a>
- **Federal Register notice 2018-02768 · published 2018-02-12 · Determination of Regulatory Review Period for Purposes of Patent Extension; DALVANCE** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2018-02-12/pdf/2018-02768.pdf) (`federal-register-2018-02768-12e5f5b2b538`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2018-02768." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2018-02768-v1 SHA-256: fd7ae3ca1130b771f35d5ec41adcf5e597ee821a30a0384eca84f28f258f4ba1.

---

<a id="federal-register-2019-09007-v1"></a>

## Federal Register notice 2019-09007

> The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

- Evidence object: `story:federal-register-2019-09007:v1`
- Evidence domain: Regulatory
- Date in source: 2019-05-03
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2019-09007/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2019-09007-v1
- Content SHA-256: `ea369119bbf6638c96dc82fe624866ef8d14b6c5670f658b60b041b6167dd28e`

### Claims and source pins

#### Headline

Federal Register notice 2019-09007 ([`federal-register-2019-09007-ca364e677eac`](#source-federal-register-2019-09007-ca364e677eac))

#### Summary

The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2019-09007-ca364e677eac`](#source-federal-register-2019-09007-ca364e677eac))

#### Paragraph 1

The Federal Register published notice 2019-09007, attributed to FDA and its parent HHS department, on 2019-05-03. Its official title is “21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2019-09007-ca364e677eac`](#source-federal-register-2019-09007-ca364e677eac))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2019-09007-ca364e677eac`](#source-federal-register-2019-09007-ca364e677eac))

### Sources

<a id="source-federal-register-2019-09007-ca364e677eac"></a>
- **Federal Register notice 2019-09007 · published 2019-05-03 · 21st Century Cures Act: Annual Compilation of Notices of Updates From the Susceptibility Test Interpretive Criteria Web Page; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2019-05-03/pdf/2019-09007.pdf) (`federal-register-2019-09007-ca364e677eac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2019-09007." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2019-09007-v1 SHA-256: ea369119bbf6638c96dc82fe624866ef8d14b6c5670f658b60b041b6167dd28e.

---

<a id="federal-register-2026-15149-v1"></a>

## Federal Register notice 2026-15149

> The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin.

- Evidence object: `story:federal-register-2026-15149:v1`
- Evidence domain: Regulatory
- Date in source: 2026-07-28
- Source checked: 2026-11-17
- Published by PeptideScanner: 2026-11-17
- Story landing page: https://peptidescanner.com/stories/federal-register-2026-15149/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2026-15149-v1
- Content SHA-256: `20a6ec7bcc25d505d2af8c9562f28639ded0d91cb63a3533b88df6c173af2876`

### Claims and source pins

#### Headline

Federal Register notice 2026-15149 ([`federal-register-2026-15149-887cde1d98e2`](#source-federal-register-2026-15149-887cde1d98e2))

#### Summary

The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2026-15149-887cde1d98e2`](#source-federal-register-2026-15149-887cde1d98e2))

#### Paragraph 1

The Federal Register published notice 2026-15149, attributed to FDA and its parent HHS department, on 2026-07-28. Its official title is “Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Dalbavancin. ([`federal-register-2026-15149-887cde1d98e2`](#source-federal-register-2026-15149-887cde1d98e2))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2026-15149-887cde1d98e2`](#source-federal-register-2026-15149-887cde1d98e2))

### Sources

<a id="source-federal-register-2026-15149-887cde1d98e2"></a>
- **Federal Register notice 2026-15149 · published 2026-07-28 · Pediatric Advisory Committee (PAC); Notice of Meeting; Establishment of a Public Docket; Request for Comments** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2026-07-28/pdf/2026-15149.pdf) (`federal-register-2026-15149-887cde1d98e2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2026-15149." Version 1, published 2026-11-17. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#federal-register-2026-15149-v1 SHA-256: 20a6ec7bcc25d505d2af8c9562f28639ded0d91cb63a3533b88df6c173af2876.

---

<a id="pubmed-pmid-29168673-dalbavancin-v1"></a>

## The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery.

> PubMed lists PMID 29168673 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2017-11-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29168673-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-09-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29168673-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-29168673-dalbavancin-v1
- Content SHA-256: `2f66dfa553005da1c29becb94213b704e9db2e56c2e1bb19af1d584ce4cfa691`

### Claims and source pins

#### Headline

The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery. ([`pubmed-observation-pmid-29168673-2018-09-26-109dac028a03`](#source-pubmed-observation-pmid-29168673-2018-09-26-109dac028a03))

#### Summary

PubMed lists PMID 29168673 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2017-11-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29168673-2018-09-26-109dac028a03`](#source-pubmed-observation-pmid-29168673-2018-09-26-109dac028a03))

#### Paragraph 1

PubMed lists PMID 29168673 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2017-11-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29168673-2018-09-26-109dac028a03`](#source-pubmed-observation-pmid-29168673-2018-09-26-109dac028a03))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29168673-2018-09-26-109dac028a03`](#source-pubmed-observation-pmid-29168673-2018-09-26-109dac028a03))

### Sources

<a id="source-pubmed-observation-pmid-29168673-2018-09-26-109dac028a03"></a>
- **The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery. · retained source version 1:2018-09-26:current:109dac028a03eb0733eba98a299a9f82a2edbb6084ee337fafede2b154d66ba1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29168673/) (`pubmed-observation-pmid-29168673-2018-09-26-109dac028a03`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-29168673-dalbavancin-v1 SHA-256: 2f66dfa553005da1c29becb94213b704e9db2e56c2e1bb19af1d584ce4cfa691.

---

<a id="pubmed-pmid-29258361-dalbavancin-v1"></a>

## Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections.

> PubMed lists PMID 29258361 in Expert opinion on drug metabolism & toxicology as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-12-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29258361-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-02-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29258361-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-29258361-dalbavancin-v1
- Content SHA-256: `db12ae178e5e1aeb042f04020cb32291ba0990c6629ca4d18eeaaa599f99bfe1`

### Claims and source pins

#### Headline

Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. ([`pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f`](#source-pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f))

#### Summary

PubMed lists PMID 29258361 in Expert opinion on drug metabolism & toxicology as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-12-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f`](#source-pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f))

#### Paragraph 1

PubMed lists PMID 29258361 in Expert opinion on drug metabolism & toxicology as Comparative Study, Journal Article, Review, with publication-date metadata of 2017-12-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f`](#source-pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f`](#source-pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f))

### Sources

<a id="source-pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f"></a>
- **Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections. · retained source version 1:2018-02-22:current:0e49fbb60f1fe6c334a527b610a23850a705b97ccda06aa2866fbcd568293072** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29258361/) (`pubmed-observation-pmid-29258361-2018-02-22-0e49fbb60f1f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-29258361-dalbavancin-v1 SHA-256: db12ae178e5e1aeb042f04020cb32291ba0990c6629ca4d18eeaaa599f99bfe1.

---

<a id="pubmed-pmid-29298166-dalbavancin-v1"></a>

## The role of dalbavancin in skin and soft tissue infections.

> PubMed lists PMID 29298166 in Current opinion in infectious diseases as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-29298166-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2019-07-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-29298166-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-29298166-dalbavancin-v1
- Content SHA-256: `ed62fbabbfe0a5a34f8ce7d10b8ff9162905f80a6e852fbede11a8851c0a45b3`

### Claims and source pins

#### Headline

The role of dalbavancin in skin and soft tissue infections. ([`pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65`](#source-pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65))

#### Summary

PubMed lists PMID 29298166 in Current opinion in infectious diseases as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65`](#source-pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65))

#### Paragraph 1

PubMed lists PMID 29298166 in Current opinion in infectious diseases as Journal Article, Review, with publication-date metadata of 2018-04 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65`](#source-pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65`](#source-pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65))

### Sources

<a id="source-pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65"></a>
- **The role of dalbavancin in skin and soft tissue infections. · retained source version 1:2019-07-18:current:6fa2a70aed654227d58dd6afc432ba0fdc586c5028cae4dce0e4032d0897dc07** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/29298166/) (`pubmed-observation-pmid-29298166-2019-07-18-6fa2a70aed65`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The role of dalbavancin in skin and soft tissue infections." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-29298166-dalbavancin-v1 SHA-256: ed62fbabbfe0a5a34f8ce7d10b8ff9162905f80a6e852fbede11a8851c0a45b3.

---

<a id="pubmed-pmid-31087630-dalbavancin-v1"></a>

## Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis.

> PubMed lists PMID 31087630 in Clinical pharmacology in drug development as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-14 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-31087630-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-05-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-31087630-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-31087630-dalbavancin-v1
- Content SHA-256: `418073d9029a17d3ba960e6f41766ac2af5c20dafb5c4afa0f015b80e2b18a9b`

### Claims and source pins

#### Headline

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. ([`pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7`](#source-pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7))

#### Summary

PubMed lists PMID 31087630 in Clinical pharmacology in drug development as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-14 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7`](#source-pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7))

#### Paragraph 1

PubMed lists PMID 31087630 in Clinical pharmacology in drug development as Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, with publication-date metadata of 2019-05-14 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7`](#source-pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7`](#source-pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7))

### Sources

<a id="source-pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7"></a>
- **Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis. · retained source version 1:2021-05-31:current:1ebcbab005e7d17ede720585fc25cfc5a099e51169f1da578675bdc8888e60cd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/31087630/) (`pubmed-observation-pmid-31087630-2021-05-31-1ebcbab005e7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-31087630-dalbavancin-v1 SHA-256: 418073d9029a17d3ba960e6f41766ac2af5c20dafb5c4afa0f015b80e2b18a9b.

---

<a id="pubmed-pmid-32223465-dalbavancin-v1"></a>

## The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

> PubMed lists PMID 32223465 in Expert review of anti-infective therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2020-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32223465-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-03-11
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32223465-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32223465-dalbavancin-v1
- Content SHA-256: `2f1d72e0b83b9deaf1b9e56051f75de9a20fcf907c061bfd7dc820aa9f084599`

### Claims and source pins

#### Headline

The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). ([`pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e`](#source-pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e))

#### Summary

PubMed lists PMID 32223465 in Expert review of anti-infective therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2020-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e`](#source-pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e))

#### Paragraph 1

PubMed lists PMID 32223465 in Expert review of anti-infective therapy as Journal Article, Research Support, Non-U.S. Gov't, Review, with publication-date metadata of 2020-03-29 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e`](#source-pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e`](#source-pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e))

### Sources

<a id="source-pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e"></a>
- **The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs). · retained source version 1:2021-03-11:current:c53e64fd0f7eefc68509a389ee78bd3beaf9f0671dc20b8180fa6679c5adbe52** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32223465/) (`pubmed-observation-pmid-32223465-2021-03-11-c53e64fd0f7e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The role of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs)." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32223465-dalbavancin-v1 SHA-256: 2f1d72e0b83b9deaf1b9e56051f75de9a20fcf907c061bfd7dc820aa9f084599.

---

<a id="pubmed-pmid-32457989-dalbavancin-v1"></a>

## Dalbavancin for the management of osteomyelitis: a major step forward?

> PubMed lists PMID 32457989 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2020-10-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32457989-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-06-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32457989-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32457989-dalbavancin-v1
- Content SHA-256: `395747d377e5cc17ff75e149955116690c5375fb129fba94e5f36d75ba866267`

### Claims and source pins

#### Headline

Dalbavancin for the management of osteomyelitis: a major step forward? ([`pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d`](#source-pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d))

#### Summary

PubMed lists PMID 32457989 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2020-10-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d`](#source-pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d))

#### Paragraph 1

PubMed lists PMID 32457989 in The Journal of antimicrobial chemotherapy as Journal Article, Review, with publication-date metadata of 2020-10-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d`](#source-pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d`](#source-pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d))

### Sources

<a id="source-pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d"></a>
- **Dalbavancin for the management of osteomyelitis: a major step forward? · retained source version 1:2021-06-22:current:f00ae6676e6dac033ef892dbc4b4be16dbd5706784c591776a3994469f64833e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32457989/) (`pubmed-observation-pmid-32457989-2021-06-22-f00ae6676e6d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin for the management of osteomyelitis: a major step forward?" Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32457989-dalbavancin-v1 SHA-256: 395747d377e5cc17ff75e149955116690c5375fb129fba94e5f36d75ba866267.

---

<a id="pubmed-pmid-32603683-dalbavancin-v1"></a>

## Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review.

> PubMed lists PMID 32603683 in International journal of antimicrobial agents as Journal Article, Systematic Review, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32603683-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32603683-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32603683-dalbavancin-v1
- Content SHA-256: `b4633983600e1059ddf619f46ca80045d28f3158d56187c5338944519b9077ee`

### Claims and source pins

#### Headline

Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review. ([`pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259`](#source-pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259))

#### Summary

PubMed lists PMID 32603683 in International journal of antimicrobial agents as Journal Article, Systematic Review, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259`](#source-pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259))

#### Paragraph 1

PubMed lists PMID 32603683 in International journal of antimicrobial agents as Journal Article, Systematic Review, with publication-date metadata of 2020-06-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259`](#source-pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259`](#source-pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259))

### Sources

<a id="source-pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259"></a>
- **Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review. · retained source version 1:2026-01-27:current:7eb2122dd25951059fdf8ef438a2e3f9d201de868c1c07152018e1b331d4568e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32603683/) (`pubmed-observation-pmid-32603683-2026-01-27-7eb2122dd259`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment of osteoarticular, cardiovascular, intravascular-catheter-related and other complicated infections with dalbavancin and oritavancin: A systematic review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32603683-dalbavancin-v1 SHA-256: b4633983600e1059ddf619f46ca80045d28f3158d56187c5338944519b9077ee.

---

<a id="pubmed-pmid-32629114-dalbavancin-v1"></a>

## Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review.

> PubMed lists PMID 32629114 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-03 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32629114-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32629114-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32629114-dalbavancin-v1
- Content SHA-256: `7a30e8d559a53ed7133c34be2e4044e60ad1d52fa33eb8c74b0ad0ba30de847a`

### Claims and source pins

#### Headline

Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review. ([`pubmed-observation-pmid-32629114-2026-01-27-151ade346d25`](#source-pubmed-observation-pmid-32629114-2026-01-27-151ade346d25))

#### Summary

PubMed lists PMID 32629114 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-03 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32629114-2026-01-27-151ade346d25`](#source-pubmed-observation-pmid-32629114-2026-01-27-151ade346d25))

#### Paragraph 1

PubMed lists PMID 32629114 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-03 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32629114-2026-01-27-151ade346d25`](#source-pubmed-observation-pmid-32629114-2026-01-27-151ade346d25))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32629114-2026-01-27-151ade346d25`](#source-pubmed-observation-pmid-32629114-2026-01-27-151ade346d25))

### Sources

<a id="source-pubmed-observation-pmid-32629114-2026-01-27-151ade346d25"></a>
- **Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review. · retained source version 1:2026-01-27:current:151ade346d25904bbe1d35e69cef6cb7cdb1707db73e4094469ddee22b6ad7a1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32629114/) (`pubmed-observation-pmid-32629114-2026-01-27-151ade346d25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin and telavancin in the treatment of infective endocarditis: a literature review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32629114-dalbavancin-v1 SHA-256: 7a30e8d559a53ed7133c34be2e4044e60ad1d52fa33eb8c74b0ad0ba30de847a.

---

<a id="pubmed-pmid-32721599-dalbavancin-v1"></a>

## Current trends in the real-life use of dalbavancin: report of a study panel.

> PubMed lists PMID 32721599 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32721599-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-05-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32721599-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32721599-dalbavancin-v1
- Content SHA-256: `f86ea980c389d6e4012d32cc948f7ad7de29225b0368e545cdabdd82eb3bd063`

### Claims and source pins

#### Headline

Current trends in the real-life use of dalbavancin: report of a study panel. ([`pubmed-observation-pmid-32721599-2021-05-27-509b7a345363`](#source-pubmed-observation-pmid-32721599-2021-05-27-509b7a345363))

#### Summary

PubMed lists PMID 32721599 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32721599-2021-05-27-509b7a345363`](#source-pubmed-observation-pmid-32721599-2021-05-27-509b7a345363))

#### Paragraph 1

PubMed lists PMID 32721599 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2020-07-25 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32721599-2021-05-27-509b7a345363`](#source-pubmed-observation-pmid-32721599-2021-05-27-509b7a345363))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32721599-2021-05-27-509b7a345363`](#source-pubmed-observation-pmid-32721599-2021-05-27-509b7a345363))

### Sources

<a id="source-pubmed-observation-pmid-32721599-2021-05-27-509b7a345363"></a>
- **Current trends in the real-life use of dalbavancin: report of a study panel. · retained source version 1:2021-05-27:current:509b7a345363a70e990d39377ba7b7de31e00627cc532c10343e4a9a502420e6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32721599/) (`pubmed-observation-pmid-32721599-2021-05-27-509b7a345363`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Current trends in the real-life use of dalbavancin: report of a study panel." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-32721599-dalbavancin-v1 SHA-256: f86ea980c389d6e4012d32cc948f7ad7de29225b0368e545cdabdd82eb3bd063.

---

<a id="pubmed-pmid-33962065-dalbavancin-v1"></a>

## Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review.

> PubMed lists PMID 33962065 in Journal of global antimicrobial resistance as Journal Article, Review, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33962065-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-07-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33962065-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-33962065-dalbavancin-v1
- Content SHA-256: `a9ee28aeeada308df917199bacc929b7466fe2d2cb58f8cf40eddf0e3763748d`

### Claims and source pins

#### Headline

Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. ([`pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706`](#source-pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706))

#### Summary

PubMed lists PMID 33962065 in Journal of global antimicrobial resistance as Journal Article, Review, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706`](#source-pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706))

#### Paragraph 1

PubMed lists PMID 33962065 in Journal of global antimicrobial resistance as Journal Article, Review, with publication-date metadata of 2021-05-04 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706`](#source-pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706`](#source-pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706))

### Sources

<a id="source-pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706"></a>
- **Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review. · retained source version 1:2021-07-01:current:cfcdf7efb706837da1119716685fc28b44641eb843d49e1ff36c95b566fa78a0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33962065/) (`pubmed-observation-pmid-33962065-2021-07-01-cfcdf7efb706`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin treatment for prosthetic joint infections in real-life: a national cohort study and literature review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-33962065-dalbavancin-v1 SHA-256: a9ee28aeeada308df917199bacc929b7466fe2d2cb58f8cf40eddf0e3763748d.

---

<a id="pubmed-pmid-34072670-dalbavancin-v1"></a>

## Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.

> PubMed lists PMID 34072670 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-05-31 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34072670-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-07-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34072670-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34072670-dalbavancin-v1
- Content SHA-256: `06476061497aa9b4ecae8854b0366f523e5efed83c421e7c75339f4f8e3aefb3`

### Claims and source pins

#### Headline

Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. ([`pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45`](#source-pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45))

#### Summary

PubMed lists PMID 34072670 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-05-31 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45`](#source-pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45))

#### Paragraph 1

PubMed lists PMID 34072670 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2021-05-31 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45`](#source-pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45`](#source-pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45))

### Sources

<a id="source-pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45"></a>
- **Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review. · retained source version 1:2021-07-10:current:0d115a587d452a8ac7550798a22d01e22cd3a342ed5c25b22a0bc8f21a2ed052** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34072670/) (`pubmed-observation-pmid-34072670-2021-07-10-0d115a587d45`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34072670-dalbavancin-v1 SHA-256: 06476061497aa9b4ecae8854b0366f523e5efed83c421e7c75339f4f8e3aefb3.

---

<a id="pubmed-pmid-34598419-dalbavancin-v1"></a>

## Dalbavancin.

> PubMed lists PMID 34598419 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Journal Article, Review, with publication-date metadata of 2021-09-30 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34598419-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-12-30
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34598419-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34598419-dalbavancin-v1
- Content SHA-256: `df7556c56f38fdf69c4c7a162d004701aab77f446e7efcb53fba2a362c3eb498`

### Claims and source pins

#### Headline

Dalbavancin. ([`pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f`](#source-pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f))

#### Summary

PubMed lists PMID 34598419 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Journal Article, Review, with publication-date metadata of 2021-09-30 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f`](#source-pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f))

#### Paragraph 1

PubMed lists PMID 34598419 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Journal Article, Review, with publication-date metadata of 2021-09-30 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f`](#source-pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f`](#source-pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f))

### Sources

<a id="source-pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f"></a>
- **Dalbavancin. · retained source version 1:2021-12-30:current:97c59327f44f302e2b31ebfbb49ca4c689373bfea67ea35c7ce46382e97707f3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34598419/) (`pubmed-observation-pmid-34598419-2021-12-30-97c59327f44f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34598419-dalbavancin-v1 SHA-256: df7556c56f38fdf69c4c7a162d004701aab77f446e7efcb53fba2a362c3eb498.

---

<a id="pubmed-pmid-34923922-dalbavancin-v1"></a>

## Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review.

> PubMed lists PMID 34923922 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2021-12-19 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34923922-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-09-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34923922-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34923922-dalbavancin-v1
- Content SHA-256: `345432a6fdfc21bf1c2bdebc0de60e2e3113b48a817dad41027acc04a7390eba`

### Claims and source pins

#### Headline

Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review. ([`pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457`](#source-pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457))

#### Summary

PubMed lists PMID 34923922 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2021-12-19 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457`](#source-pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457))

#### Paragraph 1

PubMed lists PMID 34923922 in Journal of chemotherapy (Florence, Italy) as Journal Article, Review, with publication-date metadata of 2021-12-19 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457`](#source-pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457`](#source-pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457))

### Sources

<a id="source-pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457"></a>
- **Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review. · retained source version 1:2022-09-15:current:22d242b1c45737ae583c4afd8a3462a06c4f7c6947ef5fabb19d5babd816c8cd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34923922/) (`pubmed-observation-pmid-34923922-2022-09-15-22d242b1c457`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin treatment for spondylodiscitis: multi-center clinical experience and literature review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34923922-dalbavancin-v1 SHA-256: 345432a6fdfc21bf1c2bdebc0de60e2e3113b48a817dad41027acc04a7390eba.

---

<a id="pubmed-pmid-34931283-dalbavancin-v1"></a>

## Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin.

> PubMed lists PMID 34931283 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2021-12-21 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-34931283-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-34931283-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34931283-dalbavancin-v1
- Content SHA-256: `fca14e45791fee6d9d610537416fc053aca8cec11d673a9baa197e4314c653fc`

### Claims and source pins

#### Headline

Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. ([`pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83`](#source-pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83))

#### Summary

PubMed lists PMID 34931283 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2021-12-21 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83`](#source-pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83))

#### Paragraph 1

PubMed lists PMID 34931283 in Clinical pharmacokinetics as Journal Article, Review, with publication-date metadata of 2021-12-21 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83`](#source-pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83`](#source-pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83))

### Sources

<a id="source-pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83"></a>
- **Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin. · retained source version 1:2026-10-10:current:a4a6a972ef831a9a328f0e16e824ca95264260bcad31cbc05161b5cd984100a5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/34931283/) (`pubmed-observation-pmid-34931283-2026-10-10-a4a6a972ef83`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical Pharmacokinetics and Pharmacodynamics of Dalbavancin." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-34931283-dalbavancin-v1 SHA-256: fca14e45791fee6d9d610537416fc053aca8cec11d673a9baa197e4314c653fc.

---

<a id="pubmed-pmid-35353020-dalbavancin-v1"></a>

## Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios.

> PubMed lists PMID 35353020 in Expert review of anti-infective therapy as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-04-08 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35353020-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-10-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35353020-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-35353020-dalbavancin-v1
- Content SHA-256: `1cd5df7dad65adfcd9e5e46f6a9cee77b967bfafe629b143380fd73af5a1bbb5`

### Claims and source pins

#### Headline

Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. ([`pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22`](#source-pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22))

#### Summary

PubMed lists PMID 35353020 in Expert review of anti-infective therapy as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-04-08 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22`](#source-pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22))

#### Paragraph 1

PubMed lists PMID 35353020 in Expert review of anti-infective therapy as Journal Article, Review, Research Support, Non-U.S. Gov't, with publication-date metadata of 2022-04-08 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22`](#source-pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22`](#source-pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22))

### Sources

<a id="source-pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22"></a>
- **Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. · retained source version 1:2022-10-15:current:f5411cf9fe22a137329575c5df72303eec7ec2b3c6252cd416f43f4c245bb1e7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35353020/) (`pubmed-observation-pmid-35353020-2022-10-15-f5411cf9fe22`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-35353020-dalbavancin-v1 SHA-256: 1cd5df7dad65adfcd9e5e46f6a9cee77b967bfafe629b143380fd73af5a1bbb5.

---

<a id="pubmed-pmid-35735062-dalbavancin-v1"></a>

## Global trends of dalbavancin: A bibliometric analysis.

> PubMed lists PMID 35735062 in Journal of clinical pharmacy and therapeutics as Journal Article, Review, with publication-date metadata of 2022-06-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-35735062-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-03-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-35735062-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-35735062-dalbavancin-v1
- Content SHA-256: `3d246fa6ed81ca96df45dc3e88601ec9c5ef45ec2146c52517a242c5d1495914`

### Claims and source pins

#### Headline

Global trends of dalbavancin: A bibliometric analysis. ([`pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e`](#source-pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e))

#### Summary

PubMed lists PMID 35735062 in Journal of clinical pharmacy and therapeutics as Journal Article, Review, with publication-date metadata of 2022-06-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e`](#source-pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e))

#### Paragraph 1

PubMed lists PMID 35735062 in Journal of clinical pharmacy and therapeutics as Journal Article, Review, with publication-date metadata of 2022-06-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e`](#source-pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e`](#source-pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e))

### Sources

<a id="source-pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e"></a>
- **Global trends of dalbavancin: A bibliometric analysis. · retained source version 1:2023-03-24:current:1f8b53d42c6ecfb1d1599157f0a8731f17c89355a68735d4614ba8e93dd9556a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/35735062/) (`pubmed-observation-pmid-35735062-2023-03-24-1f8b53d42c6e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Global trends of dalbavancin: A bibliometric analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-35735062-dalbavancin-v1 SHA-256: 3d246fa6ed81ca96df45dc3e88601ec9c5ef45ec2146c52517a242c5d1495914.

---

<a id="pubmed-pmid-36808371-dalbavancin-v1"></a>

## The current and future off-label uses of dalbavancin: a narrative review.

> PubMed lists PMID 36808371 in European review for medical and pharmacological sciences as Review, Journal Article, with publication-date metadata of 2023-02 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36808371-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36808371-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-36808371-dalbavancin-v1
- Content SHA-256: `f84b14baadcae4e06620990bce645073008aa88abf24062f1c2c1b8f7d53d5a1`

### Claims and source pins

#### Headline

The current and future off-label uses of dalbavancin: a narrative review. ([`pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f`](#source-pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f))

#### Summary

PubMed lists PMID 36808371 in European review for medical and pharmacological sciences as Review, Journal Article, with publication-date metadata of 2023-02 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f`](#source-pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f))

#### Paragraph 1

PubMed lists PMID 36808371 in European review for medical and pharmacological sciences as Review, Journal Article, with publication-date metadata of 2023-02 (month precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f`](#source-pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f`](#source-pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f))

### Sources

<a id="source-pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f"></a>
- **The current and future off-label uses of dalbavancin: a narrative review. · retained source version 1:2026-01-27:current:d95b5d82a92ff21a73f2d154abf6131278986cea1e9a21cf8c3356dbc9441b5a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36808371/) (`pubmed-observation-pmid-36808371-2026-01-27-d95b5d82a92f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "The current and future off-label uses of dalbavancin: a narrative review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-36808371-dalbavancin-v1 SHA-256: f84b14baadcae4e06620990bce645073008aa88abf24062f1c2c1b8f7d53d5a1.

---

<a id="pubmed-pmid-37513919-dalbavancin-v1"></a>

## Dalbavancin in Bone and Joint Infections: A Systematic Review.

> PubMed lists PMID 37513919 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-07-15 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37513919-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-08-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37513919-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-37513919-dalbavancin-v1
- Content SHA-256: `99e58f51fc0dbf2a92ecfef0e52e1af0507e47db9d35d11ca3dea0590d80a493`

### Claims and source pins

#### Headline

Dalbavancin in Bone and Joint Infections: A Systematic Review. ([`pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1`](#source-pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1))

#### Summary

PubMed lists PMID 37513919 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-07-15 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1`](#source-pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1))

#### Paragraph 1

PubMed lists PMID 37513919 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-07-15 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1`](#source-pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1`](#source-pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1))

### Sources

<a id="source-pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1"></a>
- **Dalbavancin in Bone and Joint Infections: A Systematic Review. · retained source version 1:2023-08-01:current:4c1a856a2fa10dc4765965c6b06083665aad2af304ed75cc95a6c2b7523cbda1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37513919/) (`pubmed-observation-pmid-37513919-2023-08-01-4c1a856a2fa1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin in Bone and Joint Infections: A Systematic Review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-37513919-dalbavancin-v1 SHA-256: 99e58f51fc0dbf2a92ecfef0e52e1af0507e47db9d35d11ca3dea0590d80a493.

---

<a id="pubmed-pmid-37887193-dalbavancin-v1"></a>

## A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.

> PubMed lists PMID 37887193 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-09-28 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37887193-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-10-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37887193-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-37887193-dalbavancin-v1
- Content SHA-256: `862ef016df4f34a3356f712974d6a0f73f2d5ff5fe7347aefd6a983e1adfddd4`

### Claims and source pins

#### Headline

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. ([`pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061`](#source-pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061))

#### Summary

PubMed lists PMID 37887193 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-09-28 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061`](#source-pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061))

#### Paragraph 1

PubMed lists PMID 37887193 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-09-28 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061`](#source-pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061`](#source-pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061))

### Sources

<a id="source-pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061"></a>
- **A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections. · retained source version 1:2023-10-29:current:7abcb6a38061fd1b97907c94a94e6fc015836370c92816ed80a5e26b9c2c02b2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37887193/) (`pubmed-observation-pmid-37887193-2023-10-29-7abcb6a38061`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-37887193-dalbavancin-v1 SHA-256: 862ef016df4f34a3356f712974d6a0f73f2d5ff5fe7347aefd6a983e1adfddd4.

---

<a id="pubmed-pmid-38449918-dalbavancin-v1"></a>

## Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis.

> PubMed lists PMID 38449918 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2024-02-07 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38449918-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-03-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38449918-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-38449918-dalbavancin-v1
- Content SHA-256: `776c11897f5a35f68a1c1151b536176fedddd70ab18dacda7766629ee7969484`

### Claims and source pins

#### Headline

Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis. ([`pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0`](#source-pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0))

#### Summary

PubMed lists PMID 38449918 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2024-02-07 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0`](#source-pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0))

#### Paragraph 1

PubMed lists PMID 38449918 in Open forum infectious diseases as Clinical Trial, Journal Article, with publication-date metadata of 2024-02-07 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0`](#source-pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0`](#source-pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0))

### Sources

<a id="source-pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0"></a>
- **Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis. · retained source version 1:2024-03-08:current:dab3196b3da0c40f56c185226b8a7562f8f38d939dc25b2b2b6926db0687a247** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38449918/) (`pubmed-observation-pmid-38449918-2024-03-08-dab3196b3da0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalba Got Back? Use of Dalbavancin for the Treatment of Vertebral Osteomyelitis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-38449918-dalbavancin-v1 SHA-256: 776c11897f5a35f68a1c1151b536176fedddd70ab18dacda7766629ee7969484.

---

<a id="pubmed-pmid-38533780-dalbavancin-v1"></a>

## Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review.

> PubMed lists PMID 38533780 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Letter, Review, with publication-date metadata of 2024-03-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38533780-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2024-05-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38533780-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-38533780-dalbavancin-v1
- Content SHA-256: `65c357d5b5a6c373838054e55376bb2af0ed8e51240bc84ae7f1fa45417702b8`

### Claims and source pins

#### Headline

Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review. ([`pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d`](#source-pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d))

#### Summary

PubMed lists PMID 38533780 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Letter, Review, with publication-date metadata of 2024-03-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d`](#source-pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d))

#### Paragraph 1

PubMed lists PMID 38533780 in Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia as Letter, Review, with publication-date metadata of 2024-03-27 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d`](#source-pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d`](#source-pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d))

### Sources

<a id="source-pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d"></a>
- **Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review. · retained source version 1:2024-05-18:current:ae51c30a0f8de646e7d329f982e472f1f6510a401f91c3c27b52c5dde7a898d6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38533780/) (`pubmed-observation-pmid-38533780-2024-05-18-ae51c30a0f8d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin as long-term treatment in Corynebacterium striatum Infections: a literature review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-38533780-dalbavancin-v1 SHA-256: 65c357d5b5a6c373838054e55376bb2af0ed8e51240bc84ae7f1fa45417702b8.

---

<a id="pubmed-pmid-39029624-dalbavancin-v1"></a>

## Dalbavancin for the treatment of bone and joint infections: A meta-analysis.

> PubMed lists PMID 39029624 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39029624-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-05-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39029624-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-39029624-dalbavancin-v1
- Content SHA-256: `865839024034611d1745ce2501de11dceb9a47031d7766bda5fbafa574e648e9`

### Claims and source pins

#### Headline

Dalbavancin for the treatment of bone and joint infections: A meta-analysis. ([`pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1`](#source-pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1))

#### Summary

PubMed lists PMID 39029624 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1`](#source-pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1))

#### Paragraph 1

PubMed lists PMID 39029624 in Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy as Journal Article, Meta-Analysis, Systematic Review, with publication-date metadata of 2024-07-17 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1`](#source-pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1`](#source-pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1))

### Sources

<a id="source-pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1"></a>
- **Dalbavancin for the treatment of bone and joint infections: A meta-analysis. · retained source version 1:2025-05-14:current:8f08810543f1c2154d52b64680b31ad959e56fb37e6b828d909932bfd8a31c51** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39029624/) (`pubmed-observation-pmid-39029624-2025-05-14-8f08810543f1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Dalbavancin for the treatment of bone and joint infections: A meta-analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-39029624-dalbavancin-v1 SHA-256: 865839024034611d1745ce2501de11dceb9a47031d7766bda5fbafa574e648e9.

---

<a id="pubmed-pmid-40001365-dalbavancin-v1"></a>

## Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients.

> PubMed lists PMID 40001365 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-01-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40001365-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2025-02-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40001365-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-40001365-dalbavancin-v1
- Content SHA-256: `504daaa664bc4e37ea7af27e0eee872ad446a79d4b83579a5cb209014240fa49`

### Claims and source pins

#### Headline

Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients. ([`pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e`](#source-pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e))

#### Summary

PubMed lists PMID 40001365 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-01-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e`](#source-pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e))

#### Paragraph 1

PubMed lists PMID 40001365 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2025-01-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e`](#source-pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e`](#source-pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e))

### Sources

<a id="source-pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e"></a>
- **Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients. · retained source version 1:2025-02-28:current:db5d3057354ee7f6f83ed3482b6b2736492b6e0429ee35de867e49862b26187c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40001365/) (`pubmed-observation-pmid-40001365-2025-02-28-db5d3057354e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Bridging the Gap: A Systematic Review with Expert Opinion on the Use of Dalbavancin for In-Label and Off-Label Indications in Pediatric Patients." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-40001365-dalbavancin-v1 SHA-256: 504daaa664bc4e37ea7af27e0eee872ad446a79d4b83579a5cb209014240fa49.

---

<a id="pubmed-pmid-40993014-dalbavancin-v1"></a>

## \[Translated article\] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections.

> PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-40993014-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40993014-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-40993014-dalbavancin-v1
- Content SHA-256: `3fd08f97bf5ede62524116c544d3192fc5a7f63ee808e01509e7233a3b063c23`

### Claims and source pins

#### Headline

\[Translated article\] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections. ([`pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3`](#source-pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3))

#### Summary

PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3`](#source-pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3))

#### Paragraph 1

PubMed lists PMID 40993014 in Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria as Systematic Review, Journal Article, with publication-date metadata of 2025-09-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3`](#source-pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3`](#source-pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3))

### Sources

<a id="source-pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3"></a>
- **\[Translated article\] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections. · retained source version 1:2026-05-18:current:9762e03be0f30d612f408f534042a28adf3b9ec08b59ce827cd6bb2a6a644885** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40993014/) (`pubmed-observation-pmid-40993014-2026-05-18-9762e03be0f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "\[Translated article\] Therapeutic drug monitoring of dalbavancin: A systematic review of strategies and clinical applications in the treatment of complex infections." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-40993014-dalbavancin-v1 SHA-256: 3fd08f97bf5ede62524116c544d3192fc5a7f63ee808e01509e7233a3b063c23.

---

<a id="pubmed-pmid-41892415-dalbavancin-v1"></a>

## Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review.

> PubMed lists PMID 41892415 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-03-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41892415-dalbavancin:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41892415-dalbavancin/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-41892415-dalbavancin-v1
- Content SHA-256: `c7109847e7f774058670d75a3e7cc8110ab0be9702b50bf221ed6c93c612d90f`

### Claims and source pins

#### Headline

Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review. ([`pubmed-observation-pmid-41892415-2026-08-13-65478acaa429`](#source-pubmed-observation-pmid-41892415-2026-08-13-65478acaa429))

#### Summary

PubMed lists PMID 41892415 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-03-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41892415-2026-08-13-65478acaa429`](#source-pubmed-observation-pmid-41892415-2026-08-13-65478acaa429))

#### Paragraph 1

PubMed lists PMID 41892415 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2026-03-01 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41892415-2026-08-13-65478acaa429`](#source-pubmed-observation-pmid-41892415-2026-08-13-65478acaa429))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41892415-2026-08-13-65478acaa429`](#source-pubmed-observation-pmid-41892415-2026-08-13-65478acaa429))

### Sources

<a id="source-pubmed-observation-pmid-41892415-2026-08-13-65478acaa429"></a>
- **Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review. · retained source version 1:2026-08-13:current:65478acaa4295544d0e14ff35a0f723e745e383ab50ae68c5ae5f333967fb9e8** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41892415/) (`pubmed-observation-pmid-41892415-2026-08-13-65478acaa429`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Proactive Therapeutic Drug Monitoring of Dalbavancin in the Long-Term Treatment of Chronic Infections: A Narrative Review." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/dalbavancin.json#pubmed-pmid-41892415-dalbavancin-v1 SHA-256: c7109847e7f774058670d75a3e7cc8110ab0be9702b50bf221ed6c93c612d90f.

